BAL PHARMA LTD. - 524824 - Announcement As Per Regulation 30 Of SEBI(LODR) Regulations Appointment Of Additional Director
We would like to inform the exchanges that the Board of Directors of the Company vide a resolution passed by circulation has appointed Ms. Nicola Neeladri (DIN 01997936) as Additional Director of the Company to hold office from 23.05.2023 until the conclusion of ensuing General Meeting of the Company. BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We are submitting to the exchange newspaper advertisements of abridged Audited standalone and Consolidated financial results of the Company for the quarter & F.Y ended 31.03.2023 announced by the Company on 29.05.2023 and published in Financial Express (English) and Sanjay vani (Kannada), on 30.05.2023. BAL PHARMA LTD. - 524824 - Audited Financial Results - Stand Alone And Consolidated For The Quarter And Year Ended 31.03.2023
The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended 31.03.2023. A copy of the Audited financial statements (Standalone and Consolidated) along with auditors reports with unmodified opinion are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each i.e 10%, subject to the approval of members at the ensuing Annual General Meeting of the Company. 3.Appointed Mr.M.R Krishna Murthy (Membership No. 7568) as Cost Auditor , Mr.Parameshwar Bhat (Membership No.8860) as Secretarial Auditors and Messrs. Murugesh & Co ( Membership No.002233S) as internal auditors of the Company for the financial year 2023-2024. The meeting commenced at 4.45 P.M and concluded at 6.20 P.M on 29.05.2023. BAL PHARMA LTD. - 524824 - Related Party Transactions For The Half Year Ended 31.03.2023
We are submitting to the exchanges statement of the related party transactions for the half year ended 31.03.2023, duly reviewed by our statutory auditors. BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Out Come Of The Board Meeting
The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended 31.03.2023. A copy of the Audited financial statements (Standalone and Consolidated) along with auditors reports with unmodified opinion are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each i.e 10%, subject to the approval of members at the ensuing Annual General Meeting of the Company. 3.Appointed Mr.M.R Krishna Murthy (Membership No. 7568) as Cost Auditor , Mr.Parameshwar Bhat (Membership No.8860) as Secretarial Auditors and Messrs. Murugesh & Co ( Membership No.002233S) as internal auditors of the Company for the financial year 2023-2024. The meeting commenced at 4.45 P.M and concluded at 6.20 P.M on 29.05.2023. BAL PHARMA LTD. - 524824 - Announcement Under Regulation 30 Of LODR Regulations- Up Dation Of KYC, PAN & Nomination.
We wish to inform the exchanges that the enclosed letter along with relevant annexures are sent to identified physical shareholders of the Company through our RTA , requesting them to update their PAN, KYC details and Nomination in the Company Records for smooth processing of the investors service requests. The aforesaid intimation shall be placed on the Company's website at www.balpharma.com. BAL PHARMA LTD. - 524824 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the financial year ended 31.03.2023. BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Inter Alia Approval Of Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31.03.2023.
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 ,inter alia, to consider and approve 1.audited standalone and consolidated financial results for the quarter and financial year ended 31.03.2023. 2.audited Standalone and Consolidated accounts of the Company together with Directors and Auditors reports, for F.Y ended 31.03.2023. 3. recommendation of dividend, if any for the financial year ended 31.03.2023. 4. appointment of Internal Auditors, Cost Auditors and Secretarial Auditors for F.Y 2023-24.
